Product Program year 2025 Source: CMS Open Payments

Recorlev

Drug Adrenal steroidogenesis inhibitor

NDC 72065-003-01

Open in the dashboard

General payments

$1,321,526

21,416 payments

Research payments

$304,846

90 payments

Through program year 2025, $1,321,526 in general payments and $304,846 in research payments were reported against Recorlev (Adrenal steroidogenesis inhibitor).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $721,577 10,054
2024 General $383,194 7,222
2023 General $161,085 3,515
2023 Research $99,815 27
2022 General $55,669 625
2022 Research $205,030 63

Breakdown

Who paid General payments · program years 2022–2025
  1. Xeris Pharmaceuticals, Inc. $1,321,526 21,416 payments
Top recipients General payments · program year 2025
  1. Elena Christofides Endocrinology, Diabetes & Metabolism · Columbus, OH $80,036 11% · 88 payments
  2. Ilja Hulinsky Endocrinology, Diabetes & Metabolism · Bridgeport, CT $62,916 9% · 99 payments
  3. Philip Rabito New York, NY $42,038 6% · 53 payments
  4. Saleemah Fahmi Endocrinology, Diabetes & Metabolism · Dallas, TX $24,173 3% · 48 payments
  5. Brandy Biederman Nurse Practitioner, Family · Hixson, TN $20,126 3% · 50 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $485,353 72% · 1,138 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $65,519 10% · 671 practitioners
  3. Internal Medicine $32,893 5% · 398 practitioners
  4. Family Medicine $24,604 4% · 393 practitioners
  5. Physician Assistant $18,510 3% · 274 practitioners

The top 5 of 80 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $103,130 14% · 367 recipients
  2. Ohio $93,637 13% · 206 recipients
  3. Connecticut $75,166 10% · 67 recipients
  4. Texas $73,192 10% · 298 recipients
  5. California $50,870 7% · 391 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

639

Prescriptions dispensed, refills included

Drug cost

$18,421,440

Paid at the pharmacy, in all

Prescribers

37

With 11 or more claims of it

Medicare Part D drugs matched to RECORLEV, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Recorlev Levoketoconazole Same name 37 639 $18,421,440

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 37 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Hansel Rayner Internal Medicine GA 79 $2,379,346 $739
Lee Metchick Endocrinology FL 38 $1,019,591 $10,312
Benjamin Prohaska Physician Assistant NV 34 $750,480 $205
Elena Christofides Endocrinology OH 33 $606,500 $30,328
Ronald Watts Endocrinology GA 28 $520,241 $796

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 37 with Patron
21,416 general · 90 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record